Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

South Korea · Delayed Price · Currency is KRW

17,800

-220 (-1.22%)

Aug 21, 2026, 3:30 PM KST

-7.82% (1Y)

Market Cap	218.19B -7.8%
Revenue (ttm)	274.03B +45.0%
Net Income	21.89B +49.0%
EPS	1,727.82 +52.0%
Shares Out	12.26M
PE Ratio	10.30
Forward PE	9.33
Dividend	800.00 (4.57%)
Ex-Dividend Date	Dec 29, 2025

Volume	46,273
Open	17,900
Previous Close	18,020
Day's Range	17,510 - 17,950
52-Week Range	16,580 - 25,900
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1968

Employees 586

Stock Exchange Korea Stock Exchange

Ticker Symbol 005500

Full Company Profile

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Financial Statements